Ritu Baral
Stock Analyst at TD Cowen
(2.45)
# 2,527
Out of 5,090 analysts
40
Total ratings
53.12%
Success rate
10.82%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Ritu Baral
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VERA Vera Therapeutics | Maintains: Buy | $60 → $73 | $44.90 | +62.58% | 2 | Dec 5, 2025 | |
| INSM Insmed | Maintains: Buy | $223 → $231 | $204.00 | +13.24% | 5 | Nov 20, 2025 | |
| PVLA Palvella Therapeutics | Maintains: Buy | $65 → $97 | $100.49 | -3.47% | 2 | Nov 6, 2025 | |
| RNA Avidity Biosciences | Downgrades: Hold | $78 → $74 | $71.63 | +3.31% | 2 | Oct 29, 2025 | |
| ACAD ACADIA Pharmaceuticals | Maintains: Buy | $35 → $39 | $27.44 | +42.13% | 2 | Sep 11, 2025 | |
| MDGL Madrigal Pharmaceuticals | Maintains: Buy | $390 → $554 | $577.30 | -4.04% | 2 | Aug 26, 2025 | |
| AKRO Akero Therapeutics | Initiates: Buy | $76 | $54.55 | +39.32% | 1 | Aug 4, 2025 | |
| SPRO Spero Therapeutics | Downgrades: Hold | n/a | $2.26 | - | 4 | Nov 18, 2024 | |
| ANTX AN2 Therapeutics | Downgrades: Hold | n/a | $1.10 | - | 2 | Nov 18, 2024 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Buy | $282 → $371 | $458.12 | -19.02% | 4 | Oct 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $6.39 | - | 1 | Aug 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $125 → $175 | $22.26 | +686.16% | 1 | Mar 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $79.99 | - | 2 | Nov 23, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $0.66 | - | 1 | Aug 23, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $14.89 | - | 1 | Jul 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $4.32 | - | 2 | Jul 13, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $29.36 | - | 1 | Mar 2, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $1.21 | - | 1 | Jun 29, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $2.72 | - | 2 | Jul 2, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $550.95 | - | 2 | Jan 12, 2018 |
Vera Therapeutics
Dec 5, 2025
Maintains: Buy
Price Target: $60 → $73
Current: $44.90
Upside: +62.58%
Insmed
Nov 20, 2025
Maintains: Buy
Price Target: $223 → $231
Current: $204.00
Upside: +13.24%
Palvella Therapeutics
Nov 6, 2025
Maintains: Buy
Price Target: $65 → $97
Current: $100.49
Upside: -3.47%
Avidity Biosciences
Oct 29, 2025
Downgrades: Hold
Price Target: $78 → $74
Current: $71.63
Upside: +3.31%
ACADIA Pharmaceuticals
Sep 11, 2025
Maintains: Buy
Price Target: $35 → $39
Current: $27.44
Upside: +42.13%
Madrigal Pharmaceuticals
Aug 26, 2025
Maintains: Buy
Price Target: $390 → $554
Current: $577.30
Upside: -4.04%
Akero Therapeutics
Aug 4, 2025
Initiates: Buy
Price Target: $76
Current: $54.55
Upside: +39.32%
Spero Therapeutics
Nov 18, 2024
Downgrades: Hold
Price Target: n/a
Current: $2.26
Upside: -
AN2 Therapeutics
Nov 18, 2024
Downgrades: Hold
Price Target: n/a
Current: $1.10
Upside: -
Alnylam Pharmaceuticals
Oct 21, 2024
Maintains: Buy
Price Target: $282 → $371
Current: $458.12
Upside: -19.02%
Aug 8, 2023
Initiates: Outperform
Price Target: n/a
Current: $6.39
Upside: -
Mar 22, 2023
Maintains: Outperform
Price Target: $125 → $175
Current: $22.26
Upside: +686.16%
Nov 23, 2021
Downgrades: Market Perform
Price Target: n/a
Current: $79.99
Upside: -
Aug 23, 2021
Initiates: Outperform
Price Target: n/a
Current: $0.66
Upside: -
Jul 20, 2021
Initiates: Outperform
Price Target: n/a
Current: $14.89
Upside: -
Jul 13, 2021
Initiates: Outperform
Price Target: n/a
Current: $4.32
Upside: -
Mar 2, 2021
Initiates: Outperform
Price Target: n/a
Current: $29.36
Upside: -
Jun 29, 2020
Initiates: Outperform
Price Target: n/a
Current: $1.21
Upside: -
Jul 2, 2018
Downgrades: Market Perform
Price Target: n/a
Current: $2.72
Upside: -
Jan 12, 2018
Downgrades: Market Perform
Price Target: n/a
Current: $550.95
Upside: -